Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer.
D. Rischin,B. Burmeister,P. Mitchell,M. Boyer,M. MacManus,E. Walpole,M. Feigen,M. Tin,D. Ball
DOI: https://doi.org/10.1200/JCO.2004.22.90140.7077
IF: 45.3
2004-07-15
Journal of Clinical Oncology
Abstract:7077 Background: Gefitinib ('Iressa', ZD1839) enhances tumor radioresponsiveness in preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC). The aim was to establish the recommended doses of gefitinib, carboplatin, and paclitaxel given concurrently with radical radiation therapy (RT) in patients (pts) with stage III NSCLC.
METHODS
Pts with histologic diagnosis of NSCLC, stage III disease (no pleural effusion or cervical lymphadenopathy), ECOG PS 0/1, weight loss ≤10%, and no prior RT for NSCLC were eligible. Pts received RT (60 Gy/30 fx/6 weeks) to the primary site and involved regional nodes. Concurrent oral gefitinib 250 mg/day and carboplatin AUC 2, weekly were administered with RT on dose level 1, and weekly paclitaxel was added at 25, 35, and 45 mg/m2 at dose levels 2, 3, and 4, respectively. The first 6 pts continued gefitinib after chemoRT; however, the protocol was amended to cease gefitinib at the end of chemoRT, following reports of interstitial lung disease elsewhere.
RESULTS
A total of 15 pts have been enrolled in this study from 4 institutions: median age (range), 65 (50-76) years; M/F, 11/4; stage IIIA/IIIB, 9/6; squamous-cell/large-cell/adenocarcinoma, 8/5/2. Dose escalation up to dose level 4 has been completed without any dose limiting toxicities, and additional pts are currently being treated on an expanded cohort to confirm the safety of this dose level and to obtain further efficacy data. Treatment was well tolerated: esophagitis (grade 2, n=2; grade 3, n=2); pneumonitis (grade 2, n=5; 4 of which occurred in pts who continued gefitinib after chemoRT); diarrhea (grade 2, n=1; grade 3, n=1). The PET complete response (CR) rate in 11 evaluable pts was 55%. The CT CR rate was 27% and partial response rate was 64%, for an overall response rate of 91%.
CONCLUSIONS
This regimen of concurrent gefitinib, radical RT (60 Gy) and full dose weekly carboplatin and paclitaxel was generally well tolerated. Preliminary efficacy data are encouraging and updated survival and toxicity data will be presented. [Table: see text].